Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|June 15, 2022
OWL invites AECOS attendees to July 9 networking event
Author(s)Sheryl Stevenson
Ophthalmic World Leaders (OWL) will be hosting an OWL Connect event during the American-European Congress of Ophthalmic Surgery (AECOS) 2022 Summer Symposium, Saturday, July 9.
Advertisement
Ophthalmic World Leaders (OWL) will be hosting an OWL Connect event during the American-European Congress of Ophthalmic Surgery (AECOS) 2022 Summer Symposium, Saturday, July 9.
The networking event will take place from 4:30 to 5:30 pm at The Library, St Regis Hotel, 2300 Deer Valley Drive E in Park City, Utah.
To register or for more information,
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Duravyu misses wet AMD end point again as EyePoint pivots to DME
2
CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease
3
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
4
Oculis completes randomization in PREDICT-1, the first genotype-guided registrational trial in dry eye disease
5